I am involved in a number of studies relevant to genetic testing including discrete choice surveys examining how demand for prenatal and pre-implantation genetic testing varies as a function of a number of factors (including cost and amount of risk information provided by the test), the cost effectiveness of providing a genetic test in conjunction with a smoking cessation program, and the cost effectiveness of using a genetic test to determine the appropriate treatment after an ACS.

Sample publications (click for full list)

Panattoni L*, Brown P, Te Ao B, Webster M, Gladding P. Personalised thienopyridine therapy: the cost effectiveness of genetic testing for CYP2C19 variants to guide treatment in patients with acute coronary syndromes: A New Zealand Evaluation. Pharmacoeconomics; November 2012, Volume 30, Issue 11, pp 1067-1084.